Prostate Specific Antigen Features
Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Latest Prostate Specific Antigen News
Diagnostic usefulness of magnetic resonance imaging/ultrasound (MRI/US) fusion targeted prostate biopsy optimized in PSA level of 5.2 ng/mL or higher.
Greater PSA increases seen in older men and those with lower baseline testosterone.
PSA levels at day 30 found to predict biochemical relapse risk in men with positive surgical margins.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.
Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
This parameter can identify prostate cancer patients for whom adjuvant radiation therapy after radical prostatectomy may be of no benefit.
PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.
Men diagnosed with low-risk prostate cancer today have lower PSA levels and tumor volume than men 15 years ago.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
Higher circulating tumor cell counts are associated with an increased risk of death.
Trend follows the 2012 release of a U.S. Preventive Services Task Force recommendation against such testing.
Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Statin Plus Metformin May Reduce Prostate Cancer Relapse Risk
- Erectile Dysfunction (ED) Linked to Early Vascular Disease
- Testosterone Therapy Does Not Increase Cardiovascular Risk
- Have malpractice award caps made any difference in medical practice?
- 'Jekyll & Hyde' Molecule Could Lead to Aggressive Prostate Cancer (PCa)
- Optimal PSA Threshold For Targeted Biopsy Identified
- Plant-Based Phosphorus Best for Kidney Disease (CKD) Patients
- Testosterone Replacement Therapy (TRT) Beneficial in Diabetes Mellitus Patients
- Stopping Renal Cell Carcinoma (mRCC) Drugs Induces Tumor Flare
- Red Meat Contributes to Cardiovascular Disease (CVD) Risk Due to Gut Bacteria